Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung cancer (NSCLC). However, no associated biomarker is validated in clinical practice with this drug. We investigated herein immune-related blood markers in patients with advanced NSCLC treated with nivolumab. Plasma o...

Descripció completa

Dades bibliogràfiques

Autors principals:	Adrien Costantini, Catherine Julie, Coraline Dumenil, Zofia Hélias-Rodzewicz, Julie Tisserand, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Jean-François Emile, Etienne Giroux Leprieur
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2018-08-01
Col·lecció:	OncoImmunology
Matèries:	nivolumab non-small cell lung cancer plasma pd-l1 pd-l2 granzyme b interleukine-2 interferon-γ microrna biomarker
Accés en línia:	http://dx.doi.org/10.1080/2162402X.2018.1452581
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!